What is Corbus Pharmaceu's earnings per share (EPS)?

Corbus Pharmaceu (CRBP) reported diluted earnings per share of $-5.90 for fiscal year 2025. This represents a -60.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Corbus Pharmaceu Financials

CRBP

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Corbus Pharmaceu (CRBP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CRBP FY2025 2026-04-22

Corbus is running on equity-funded research spend, with cash burn driven by development activity rather than leverage or physical expansion.

FY2025’s higher cash balance of $28.5M hides a sharper operating drain: operating cash burn widened to -$64.5M, so the year-end cash number alone understates how fast funds were being consumed. That deterioration lines up with R&D spending jumping to $70.1M while financing supplied $77.4M; with capex negligible, the business is consuming cash to fund research activity rather than to build a fixed-asset base.

The balance sheet has been recapitalized: FY2023 showed negative equity of -$6.9M, a sign that past losses had overtaken the capital base. By FY2025, equity reached $147.5M and no long-term debt was reported, so the company now looks financed mainly by shareholders instead of lenders.

The share count jumped from 12.2M to 17.6M in the latest year, which helps explain how liquidity improved despite deeper cash burn. With SG&A easing to $15.2M, that new capital appears to be supporting a much larger research effort rather than a growing administrative footprint.

Financial Health Signals

Financial Profile 33/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Corbus Pharmaceu's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Corbus Pharmaceu carries a low D/E ratio of 0.14, meaning only $0.14 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 8.07, Corbus Pharmaceu holds $8.07 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Returns

Corbus Pharmaceu generates a -53.2% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -28.2% the prior year.

Piotroski F-Score Weak

1/9

Corbus Pharmaceu passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.82x

For every $1 of reported earnings, Corbus Pharmaceu generates $0.82 in operating cash flow (-$64.5M OCF vs -$78.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$85.1M

YoY-76.8%

Corbus Pharmaceu's EBITDA was -$85.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 76.8% from the prior year.

Net Income

-$78.5M

YoY-95.3%

Corbus Pharmaceu reported -$78.5M in net income in fiscal year 2025. This represents a decrease of 95.3% from the prior year.

EPS (Diluted)

$-5.90

YoY-60.3%

Corbus Pharmaceu earned $-5.90 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 60.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$64.5M

YoY-54.3%

Corbus Pharmaceu generated -$64.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 54.3% from the prior year.

Cash & Debt

$28.5M

YoY+65.7%

5Y CAGR-19.7%

10Y CAGR+8.7%

Corbus Pharmaceu held $28.5M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

18M

YoY+44.6%

5Y CAGR-29.2%

10Y CAGR-7.3%

Corbus Pharmaceu had 18M shares outstanding in fiscal year 2025. This represents an increase of 44.6% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-53.2%

YoY-25.0pp

5Y CAGR+192.5pp

10Y CAGR+45.3pp

Corbus Pharmaceu's ROE was -53.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 25.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$70.1M

YoY+117.5%

5Y CAGR-6.5%

10Y CAGR+28.1%

Corbus Pharmaceu invested $70.1M in research and development in fiscal year 2025. This represents an increase of 117.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$7K

5Y CAGR-57.1%

10Y CAGR-24.4%

Corbus Pharmaceu invested $7K in capex in fiscal year 2025, funding long-term assets and infrastructure.

CRBP Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	$0-100.0%	$882K-77.6%	$3.9M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$70.1M+117.5%	$32.2M+3.4%	$31.2M+93.1%	$16.1M-55.7%	$36.4M-62.9%	$98.3M
SG&A Expenses	$15.2M-7.8%	$16.5M+18.6%	$13.9M-25.6%	$18.7M-8.5%	$20.4M-28.3%	$28.5M
Operating Income	-$85.3M-75.1%	-$48.7M-8.1%	-$45.1M-13.2%	-$39.8M+28.9%	-$56.0M+54.4%	-$122.8M
Interest Expense	$0-100.0%	$1.8M-52.6%	$3.8M+22.7%	$3.1M+14.3%	$2.7M+140.5%	$1.1M
Income Tax	$0	$0	N/A	N/A	N/A	N/A
Net Income	-$78.5M-95.3%	-$40.2M+9.9%	-$44.6M-5.3%	-$42.3M+7.2%	-$45.6M+59.0%	-$111.3M
EPS (Diluted)	$-5.90-60.3%	$-3.68+64.3%	$-10.31-1.6%	$-10.15+9.0%	$-11.15	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$19.8M	N/A	$20.9M+37.4%	$15.2M-2.9%	$15.6M	N/A	$10.8M+57.4%	$6.9M
SG&A Expenses	$4.5M	N/A	$3.6M-10.3%	$4.0M-4.1%	$4.1M	N/A	$4.7M+13.9%	$4.1M
Operating Income	-$24.3M	N/A	-$24.4M-27.5%	-$19.2M+3.2%	-$19.8M	N/A	-$15.5M-41.1%	-$11.0M
Interest Expense	N/A	N/A	$0	$0	$0	N/A	$400K-38.7%	$652K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$23.0M	N/A	-$23.3M-32.2%	-$17.7M-4.0%	-$17.0M	N/A	-$13.8M-37.9%	-$10.0M
EPS (Diluted)	$-1.23	N/A	$-1.90-31.9%	$-1.44-3.6%	$-1.39	N/A	$-1.15-27.8%	$-0.90

CRBP Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$168.2M+7.9%	$155.9M+451.4%	$28.3M-57.4%	$66.3M-38.4%	$107.7M+5.3%	$102.3M
Current Assets	$167.0M+9.1%	$153.0M+549.7%	$23.5M-60.9%	$60.2M-39.9%	$100.2M+8.8%	$92.1M
Cash & Equivalents	$28.5M+65.7%	$17.2M+25.3%	$13.7M-19.3%	$17.0M-32.0%	$25.0M-70.7%	$85.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$20.7M+53.8%	$13.5M-61.8%	$35.2M+5.6%	$33.3M-13.7%	$38.6M-32.3%	$57.0M
Current Liabilities	$20.7M+75.1%	$11.8M-62.9%	$31.9M+152.3%	$12.6M-25.7%	$17.0M-46.7%	$31.9M
Long-Term Debt	N/A	N/A	$0-100.0%	$16.0M+2.2%	$15.6M-13.3%	$18.0M
Total Equity	$147.5M+3.6%	$142.4M+2162.7%	-$6.9M-120.9%	$33.0M-52.3%	$69.1M+52.6%	$45.3M
Retained Earnings	-$555.4M-16.5%	-$476.9M-9.2%	-$436.7M-11.4%	-$392.1M-12.1%	-$349.7M-15.0%	-$304.1M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$144.5M-14.1%	$168.2M+53.6%	$109.5M-12.4%	$125.1M-10.6%	$139.9M-10.2%	$155.9M-5.1%	$164.2M+8.0%	$152.0M
Current Assets	$143.6M-14.0%	$167.0M+55.2%	$107.6M-12.4%	$122.8M-10.6%	$137.4M-10.2%	$153.0M-4.9%	$160.9M+8.5%	$148.3M
Cash & Equivalents	$25.7M-9.9%	$28.5M+5.6%	$27.0M+34.6%	$20.0M+6.1%	$18.9M+9.9%	$17.2M-11.5%	$19.4M-18.0%	$23.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$18.1M-12.3%	$20.7M+19.1%	$17.4M+23.2%	$14.1M+9.9%	$12.8M-4.7%	$13.5M-1.6%	$13.7M-48.3%	$26.4M
Current Liabilities	$18.1M-12.3%	$20.7M+21.3%	$17.1M+28.0%	$13.3M+14.7%	$11.6M-1.7%	$11.8M+1.7%	$11.6M-51.5%	$24.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$126.3M-14.3%	$147.5M+60.1%	$92.1M-17.0%	$111.0M-12.7%	$127.1M-10.8%	$142.4M-5.4%	$150.5M+19.9%	$125.5M
Retained Earnings	-$578.4M-4.1%	-$555.4M-3.8%	-$534.9M-4.6%	-$511.5M-3.6%	-$493.9M-3.6%	-$476.9M-2.0%	-$467.4M-3.0%	-$453.6M

CRBP Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$64.5M-54.3%	-$41.8M-15.8%	-$36.1M+3.8%	-$37.5M+22.1%	-$48.2M+51.7%	-$99.7M
Capital Expenditures	$7K	$0	$0-100.0%	$13K-75.2%	$54K-88.8%	$484K
Free Cash Flow	-$64.5M-54.3%	-$41.8M-15.8%	-$36.1M+3.9%	-$37.6M+22.1%	-$48.2M+51.8%	-$100.2M
Investing Cash Flow	-$1.6M+98.6%	-$121.3M-440.4%	$35.6M+18.5%	$30.1M+141.0%	-$73.4M-15053.3%	-$484K
Financing Cash Flow	$77.4M-53.5%	$166.6M+6004.9%	-$2.8M-428.7%	-$534K-100.9%	$60.8M-60.7%	$154.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$25.6M-60.6%	-$15.9M-2.4%	-$15.6M+6.3%	-$16.6M-1.1%	-$16.4M-50.1%	-$10.9M+21.5%	-$13.9M-55.9%	-$8.9M
Capital Expenditures	$6K	N/A	N/A	N/A	$0	N/A	N/A	N/A
Free Cash Flow	-$25.6M	N/A	N/A	N/A	-$16.4M	N/A	N/A	N/A
Investing Cash Flow	$22.5M+139.3%	-$57.1M-391.0%	$19.6M+10.7%	$17.7M-2.1%	$18.1M+107.6%	$8.7M+156.8%	-$15.4M+6.5%	-$16.4M
Financing Cash Flow	N/A	$74.6M+2515.7%	$2.9M	$0	$0+100.0%	-$13K-100.1%	$25.0M-28.4%	$35.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CRBP Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	-6350.1%-3230.9pp	-3119.2%
Net Margin	N/A	N/A	N/A	N/A	-5176.4%-2350.3pp	-2826.1%
Return on Equity	-53.2%-25.0pp	-28.2%	N/A	-128.4%-62.3pp	-66.0%+179.7pp	-245.8%
Return on Assets	-46.7%-20.9pp	-25.8%+132.0pp	-157.8%-93.9pp	-63.9%-21.5pp	-42.4%+66.4pp	-108.8%
Current Ratio	8.07-4.9	12.94+12.2	0.74-4.0	4.76-1.1	5.89+3.0	2.89
Debt-to-Equity	0.14+0.0	0.09+0.1	0.00-0.5	0.48+0.3	0.23-0.2	0.40
FCF Margin	N/A	N/A	N/A	N/A	-5471.0%-2926.8pp	-2544.2%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-18.2%	N/A	-25.3%-9.4pp	-15.9%-2.5pp	-13.4%	N/A	-9.2%-1.2pp	-8.0%
Return on Assets	-15.9%	N/A	-21.3%-7.2pp	-14.1%-2.0pp	-12.1%	N/A	-8.4%-1.8pp	-6.6%
Current Ratio	7.92-0.2	8.07+1.8	6.31-2.9	9.21-2.6	11.82-1.1	12.94-0.9	13.84+7.7	6.18
Debt-to-Equity	0.140.0	0.14-0.0	0.19+0.1	0.13+0.0	0.100.0	0.090.0	0.09-0.1	0.21
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Biomea Fusion, Inc. BMEA

$91.8M

Pyxis Oncology, Inc. PYXS

$112.8M

Kala Pharmaceuticals Inc KALA

$38.3M

Equillium EQ

$185.9M

Fate Therapeutic FATE

$230.8M

Frequently Asked Questions

Is Corbus Pharmaceu profitable?

No, Corbus Pharmaceu (CRBP) reported a net income of -$78.5M in fiscal year 2025.

What is Corbus Pharmaceu's EBITDA?

Corbus Pharmaceu (CRBP) had EBITDA of -$85.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Corbus Pharmaceu's return on equity (ROE)?

Corbus Pharmaceu (CRBP) has a return on equity of -53.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Corbus Pharmaceu's free cash flow?

Corbus Pharmaceu (CRBP) generated -$64.5M in free cash flow during fiscal year 2025. This represents a -54.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Corbus Pharmaceu's operating cash flow?

Corbus Pharmaceu (CRBP) generated -$64.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Corbus Pharmaceu's total assets?

Corbus Pharmaceu (CRBP) had $168.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Corbus Pharmaceu's capital expenditures?

Corbus Pharmaceu (CRBP) invested $7K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Corbus Pharmaceu spend on research and development?

Corbus Pharmaceu (CRBP) invested $70.1M in research and development during fiscal year 2025.

How many shares does Corbus Pharmaceu have outstanding?

Corbus Pharmaceu (CRBP) had 18M shares outstanding as of fiscal year 2025.

What is Corbus Pharmaceu's current ratio?

Corbus Pharmaceu (CRBP) had a current ratio of 8.07 as of fiscal year 2025, which is generally considered healthy.

What is Corbus Pharmaceu's debt-to-equity ratio?

Corbus Pharmaceu (CRBP) had a debt-to-equity ratio of 0.14 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Corbus Pharmaceu's return on assets (ROA)?

Corbus Pharmaceu (CRBP) had a return on assets of -46.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Corbus Pharmaceu's cash runway?

Based on fiscal year 2025 data, Corbus Pharmaceu (CRBP) had $28.5M in cash against an annual operating cash burn of $64.5M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Corbus Pharmaceu's Piotroski F-Score?

Corbus Pharmaceu (CRBP) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Corbus Pharmaceu's earnings high quality?

Corbus Pharmaceu (CRBP) has an earnings quality ratio of 0.82x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Corbus Pharmaceu?

Corbus Pharmaceu (CRBP) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.